泰国白喉疫情期间成人接种1剂、2剂和3剂系列破伤风-白喉类毒素减量疫苗(Td)后的血清保护率
在泰国白喉疫情期间,研究纳入160名医护人员和161名20-60岁成人,接种前测白喉抗毒素(DAT)水平,按4-8周和6-12个月间隔安排第2、3剂Td,每剂后4周测DAT。基线血清保护率为32.6%,接种1剂后升至87.1%(95%CI 83.4-90.8%),追加剂次后略升,30-49岁人群免疫应答最低。作者建议疫情期间成人接种1剂Td,1980年前出生者可考虑2剂系列。
要点
- 基线血清保护率为32.6%,接种1剂Td后升至87.1%(95%CI 83.4-90.8%)。
- 追加剂次后血清保护率仅略升,30-49岁人群免疫应答最低。
- 作者建议疫情期间成人接种1剂Td,1980年前出生者可考虑2剂系列。
核心结论
- 作者建议白喉疫情期间成人接种1剂Td,1980年前出生者可考虑2剂系列。
研究设计与样本
- 研究纳入160名医护人员和161名20-60岁成人,接种前测白喉抗毒素(DAT)水平。
- 按第2剂4-8周、第3剂6-12个月间隔安排Td,每剂后4周测DAT。
- DAT≥0.1 IU/mL为血清保护,≥1 IU/mL为长期血清保护,达到长期保护者不再追加剂次。
主要发现
- 基线血清保护率为32.6%,接种1剂后升至87.1%(95%CI 83.4-90.8%)。
- 追加剂次后血清保护率仅略升。
- 30-49岁人群免疫应答最低。
关键数值与推荐
- DAT≥0.1 IU/mL判定为血清保护,≥1 IU/mL判定为长期血清保护。
- 基线血清保护率32.6%,1剂后87.1%(95%CI 83.4-90.8%)。
临床怎么用
- 作者建议白喉疫情期间成人接种1剂Td。
- 作者建议1980年前出生者可考虑2剂系列。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To evaluate seroprotection of different dosing strategies of reduced-diphtheria-tetanus-toxoid vaccine (Td) for adults during a diphtheria outbreak in Thailand, we enrolled 160 healthcare workers and 161 adults aged 20-60 years old and measured diphtheria antitoxin (DAT) level before administration of a Td vaccine. We scheduled a second Td at 4-8 weeks and a third Td at 6-12 months interval. DAT was measured 4 weeks after each dose. DAT levels of ≥0.1 and ≥1 IU/mL were considered as seroprotective and long-term seroprotective. Persons achieving long-term seroprotection were not given a further dose. The baseline seroprotection rate was 32.6%, which increased to 87.1% (95% confidence interval, 83.4-90.8%) after one dose. The seroprotection rate increased slightly with additional doses. The immune response was lowest among persons 30-49 years of age. We suggest 1-dose Td for adults during a diphtheria outbreak, and a 2-dose series being considered for those born before 1980.
引用
- Suntarattiwong P, Vandepitte WP, Singhamatr P, et al. Seroprotection rate in adults after 1-dose, 2-dose, and 3-dose series of a reduced-diphtheria-tetanus toxoid vaccine (Td) during a diphtheria outbreak in Thailand. Vaccine. 2020. PMID: 31987691. doi:10.1016/j.vaccine.2020.01.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。